Enzo Biochem Appoints Dr. Mohan Chellani, 15-Year Industry Veteran, Vice President of Scientific Affairs at Enzo Clinical Labs

Enzo Biochem Appoints Dr. Mohan Chellani, 15-Year Industry Veteran, Vice President of Scientific Affairs at Enzo Clinical Labs

NEW YORK--(Business Wire)--
Enzo Biochem, Inc. (NYSE:ENZ) today announced the appointment of Mohan Chellani,
Ph.D., formerly a senior manager with Quest Diagnostics, as Vice President of
Scientific Affairs at its Enzo Clinical Labs subsidiary. He will oversee all
aspects of the Labs` Molecular Diagnostic`s strategy and implementation,
including serving as a key interface with Enzo Life Sciences, another Enzo
subsidiary.

Enzo Biochem is a biotechnology company specializing in gene identification and
genetic and immune regulation technologies for diagnostic and therapeutic
applications and laboratory services.

"Dr. Chellani adds outstanding experience that will greatly benefit us," said
Dr. Kevin Krenitsky, President, Enzo Clinical Labs. "We are on target at the
Labs to not only capitalize on our progress in quality improvement, but also to
further our growth strategy to broaden our capabilities in molecular diagnostics
and other new dynamic, esoteric tests in line with today`s advances in medicine.
Dr. Chellani is an important addition to our team, and we are pleased to have
him join us."

Dr. Chellani, with over 15 years experience in the clinical laboratory business,
most recently was Head of Science and Innovation Portfolio Development at Quest
Diagnostics. Among his responsibilities were growing Quest`s esoteric testing
business, introducing assays and regionalized tests, and directing product
development collaborations with academic and industry partners. Previously, Dr.
Chellani served as a Senior Scientist in molecular immunology at Abbott
Laboratories, head of Molecular Biology at PerSeptive Diagnostics, director of
business development for biocalorimetric assays at MicroCal Inc., and Program
Director, Biomics, at Perkin Elmer Life Sciences.

About Enzo

Enzo Biochem is engaged in the research, development, manufacture and licensing
of innovative health care products and technologies based on molecular biology
and genetic engineering techniques, and in providing diagnostic services to the
medical community. Enzo`s Life Sciences division develops, produces and markets
proprietary labeling and detection products for gene sequencing, genetic
analysis and immunological research among others. Its catalog of over 40,000
products serves the molecular biology, drug discovery and pathology research
markets. The Company's therapeutic division is in various stages of clinical
evaluation of its proprietary immune regulation medicines for uveitis and
Crohn's disease and conducts pre-clinical research on several candidate
compounds aimed at producing new mineral and organic bone, including technology
that could provide therapy for osteoporosis and fractures, among other
applications. Enzo`s Clinical Labs division provides routine and esoteric
reference laboratory services for physicians in the New York Metropolitan and
New Jersey areas. Underpinning the Company`s technology and operations is an
extensive intellectual property estate in which Enzo owns or licenses over 230
patents worldwide, and has pending applications for over 200 more. For more
information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release
may be considered "forward-looking" statements within the meaning of Section 27A
of the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. Such statements include declarations regarding
the intent, belief or current expectations of the Company and its management.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and uncertainties
that could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of developments
occurring after the date of this press release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.